Clinical trials
Liver Cell Carcinoma clinical trials
Below are recruiting liver cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 443 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06509568RecruitingPhase 2
Chemoradiation plus immunotherapy before surgery for esophageal cancer
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
Hangzhou, ZhejiangAges 18–75 - NCT06255223RecruitingPhase 2
Radiation therapy plus immunotherapy for advanced kidney cancer
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
Nanjing, JiangsuAges 18–80 - NCT06228066RecruitingPhase 2
Lurbinectedin with or without avelumab for small cell bladder cancer
This clinical trial tests a drug called lurbinectedin, given alone or with avelumab (an immunotherapy), for people with small cell bladder cancer or similar high-grade neuroendocrine tumors that have spread. The goal is to see if combining these drugs helps shrink or control the cancer better.
Bethesda, MarylandAges 18–120 - NCT05945875RecruitingPhase 1
Dual scans to find head and neck cancer spread
This early-stage study tests two different imaging (scanning) methods to better detect head and neck cancer. Your results from the scans may help doctors see where disease is before standard surgery to remove lymph nodes in the neck.
Nashville, TennesseeAges 19 years+ - NCT05901545RecruitingPhase 1
Test an iodine-labeled drug to map neck lymph nodes
This Phase 1 study tests a labelling of panitumumab with iodine (111In) to see how well it can identify lymph nodes in head and neck cancer before surgery. The goal is to improve lymph node staging (which can help guide treatment), with the main focus on safety and early performance.
Nashville, TennesseeAges 19 years+ - NCT05048212RecruitingPhase 2
Nivolumab, ipilimumab, and cabozantinib for kidney cancer brain spread
This Phase 2 study tests how well nivolumab plus ipilimumab, along with cabozantinib, treats untreated or worsening kidney cancer that has spread to the brain. It may help shrink brain tumors and slow the disease when standard local brain treatments aren’t the right option.
Houston, TexasAges 18 years+ - NCT06687941RecruitingPhase 1
Trial of AST-201 for GPC3-positive advanced solid tumors
This trial tests a new drug called AST-201 for people with advanced solid tumors that have a specific protein (GPC3). The study aims to see how safe and well-tolerated the drug is, and how the body processes it.
Goyang-si, Gyeonggi-doAges 19 years+ - NCT05952947RecruitingPhase 1
Study drug for HPV18-positive solid tumors with a specific immune marker
This Phase 1 trial tests HRYZ-T101 injection for people whose solid cancer is HPV18-positive and who have the HLA-DRB1*0901 immune marker. It is meant for people whose cancer has returned or spread and who have few or no effective treatment options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06176989RecruitingPhase 2
Enasidenib for IDH2-mutated sinonasal and skull base tumors
This trial tests an oral targeted therapy called enasidenib for people with rare head and neck cancers that have an IDH2 gene mutation. The goal is to see if this drug can shrink or slow the growth of these tumors.
Bethesda, MarylandAges 18–120 - NCT06418087RecruitingPhase 2
Durvalumab plus chemotherapy for advanced LCNEC
This trial tests a combination of a new immunotherapy drug (durvalumab) with standard chemotherapy for people with a rare, advanced form of lung cancer called LCNEC. It aims to see if this combination can shrink tumors or slow the cancer’s growth better than chemotherapy alone.
Bologna, BOAges 18 years+ - NCT07781072RecruitingPhase 2
Immunotherapy plus radiation for advanced head and neck cancer
This trial tests a combination of an immunotherapy drug (sintilimab) with radiation and chemotherapy for people with advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT05286619RecruitingPhase 2
Pembrolizumab with chemotherapy for recurrent head and neck cancer
This trial studies whether pembrolizumab plus chemotherapy (platinum and gemcitabine) can control recurrent or metastatic head and neck squamous cell carcinoma that can’t be cured with local treatments. It may help shrink tumors and slow disease growth in people who haven’t had cancer medicines for this stage before.
Kuala LumpurAges 18 years+ - NCT06709417RecruitingPhase 2
Immunotherapy plus chemo and radiation for advanced esophageal cancer
This trial is testing whether giving a combination of an immunotherapy drug (sintilimab) with chemotherapy, followed by radiation plus more chemotherapy (concurrent chemoradiotherapy), can help people with advanced esophageal cancer that cannot be removed surgically. The goal is to see if this approach shrinks the tumor and improves outcomes.
Shanghai, Shanghai MunicipalityAges 20–75 - NCT07545967RecruitingPhase 1
Re-radiation and Chidamide for Recurrent Head and Neck Cancer
This trial tests combining re-radiation (radiation therapy given a second time) with a drug called chidamide to treat head and neck cancer that has come back after previous radiation. The goal is to see if this combination can help patients whose cancer cannot be removed by surgery or who cannot have surgery.
Chengdu, SichuanAges 18–75 - NCT06470217RecruitingPhase 2
Study of tirilizumab plus chemo for advanced oral cancer
This trial tests a combination of immunotherapy (tirilizumab) and two chemotherapy drugs (albumin-bound paclitaxel and cisplatin) for people with advanced but removable oral cancer. The goal is to see if this treatment shrinks the tumor before surgery and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07408063RecruitingPhase 2
Study of new drug for advanced head and neck cancer
This trial tests a new drug (GSK5764227) for head and neck cancer that has spread or come back. It looks at your tumor's biomarkers to understand why some people respond to treatment. You may need to have had certain prior treatments depending on which group you join.
Toronto, OntarioAges 18 years+ - NCT07370337RecruitingPhase 2
Chemotherapy plus immunotherapy for ear canal cancer
This trial tests combining chemotherapy with the immunotherapy drug tislelizumab for advanced squamous cell carcinoma of the ear canal. It may help shrink tumors that haven't spread to other parts of the body.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07369882Recruiting
Less extensive surgery after immunotherapy for advanced head and neck cancer
This trial compares a less extensive surgery to the standard surgery for patients with advanced head and neck cancer who have responded well to initial chemotherapy and immunotherapy. The goal is to see if a smaller operation can be just as effective while causing fewer side effects.
Guangzhou, GuangdongAges 18–75 - NCT06744296Recruiting
ctDNA surveillance for HPV-negative head and neck cancer
This trial uses a blood test to look for tiny bits of tumor DNA after treatment for head and neck cancer. It aims to see if this test can detect any remaining cancer cells early, so you and your doctor can make informed decisions.
Boston, MassachusettsAges 18 years+ - NCT06828588RecruitingEarly Phase 1
A new imaging test for people on HER2 cancer therapy
This study tests a new imaging drug called [68Ga]Ga-ABY-025 to see how well it shows HER2-positive tumors in people who are about to start or have just started HER2-targeted cancer therapy. It may help doctors see if the treatment is working.
Nashville, TennesseeAges 18 years+ - NCT06339619RecruitingPhase 2
Combination immunotherapy for advanced esophageal cancer after prior treatment
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
Guangzhou, GuangdongAges 18–75 - NCT07636785RecruitingPhase 1/Phase 2
VMD-102 Drug Study for Advanced Cancers
This study tests a new drug called VMD-102 in patients with advanced liver cancer, melanoma, kidney cancer, lung cancer, or colon cancer that hasn't responded to standard treatments. The trial will help determine if VMD-102 is safe and effective at slowing or stopping cancer growth.
Scottsdale, ArizonaAges 18–75 - NCT06084234RecruitingPhase 4
National liver cancer screening trial
This trial is testing a new way to screen for liver cancer in people with cirrhosis or chronic hepatitis B. It aims to find cancer earlier so it can be treated more effectively.
Los Angeles, CaliforniaAges 18–85 - NCT07111455Recruiting
Oral bacteria changes with chemoimmunotherapy for mouth cancer
This study is testing whether a combination of chemotherapy and immunotherapy before surgery can help treat advanced oral cancer. Researchers will also look at how the cancer changes the bacteria in your mouth.
Guangzhou, GuangdongAges 18–80
Hear when a new Liver Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cell carcinoma?
- Yes. Clin2 currently lists 443 recruiting liver cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.